Literature DB >> 23146297

Neuroproteomics: an insight into ALS.

D M F Mendonça1, L Pizzati, K Mostacada, S C de S Martins, R Higashi, L Ayres Sá, V Moura Neto, L Chimelli, A M B Martinez.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of unknown aetiology. Diagnosis is made through physical examination, electrophysiological findings, and by excluding other conditions. There is not a single biomarker that concludes the diagnosis. The aim of this study was to investigate differentially expressed proteins in cerebrospinal fluid (CSF) of ALS patients compared to control subjects, with the purpose to identify a panel of possible biomarkers for the disease. The differentially expressed spots/proteins were submitted to two-dimensional (2D) electrophoresis and recognized with matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry. Parkin-like and many iron and zinc binding were some of the proteins found in ALS CSF. Parkin is a ligase involved in ubiquitin-proteasome pathway and mutations in the parkin gene are the most common cause of recessive familial Parkinson's disease. Iron and zinc are involved with many important metabolic processes and are related to neurodegenerative disease. Common features of ALS comprise failure of the ubiquitin-proteasome system and increased levels of metal ions in the brain. Therefore, the identification of these proteins can be a significant step in ALS research. These and other identified proteins are discussed in this study.

Entities:  

Mesh:

Year:  2012        PMID: 23146297     DOI: 10.1179/1743132812Y.0000000092

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  5 in total

1.  Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite.

Authors:  Marco Vinceti; Nikolay Solovyev; Jessica Mandrioli; Catherine M Crespi; Francesca Bonvicini; Elisa Arcolin; Eleni Georgoulopoulou; Bernhard Michalke
Journal:  Neurotoxicology       Date:  2013-05-31       Impact factor: 4.294

Review 2.  Alternative Splicing of ALS Genes: Misregulation and Potential Therapies.

Authors:  Benedetta Perrone; Valentina La Cognata; Teresa Sprovieri; Carmine Ungaro; Francesca Luisa Conforti; Sebastiano Andò; Sebastiano Cavallaro
Journal:  Cell Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.046

3.  Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA).

Authors:  Darija Šoltić; Melissa Bowerman; Joanne Stock; Hannah K Shorrock; Thomas H Gillingwater; Heidi R Fuller
Journal:  Brain Sci       Date:  2018-12-04

4.  Bayesian Network as a Decision Tool for Predicting ALS Disease.

Authors:  Hasan Aykut Karaboga; Aslihan Gunel; Senay Vural Korkut; Ibrahim Demir; Resit Celik
Journal:  Brain Sci       Date:  2021-01-23

5.  Intricate effects of primary motor neuronopathy on contractile proteins and metabolic muscle enzymes as revealed by label-free mass spectrometry.

Authors:  Ashling Holland; Thomas Schmitt-John; Paul Dowling; Paula Meleady; Michael Henry; Martin Clynes; Kay Ohlendieck
Journal:  Biosci Rep       Date:  2014-07-01       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.